Objective: To evaluate the toxicity and efficacy of combination regimen with oxaliplatin plus fluorouracil and leucovorin(FOLFOX) as post-operative adjuvant chemotherapy in local advanced gastric cancer.
Methods: Twenty-five gastric cancer patients, 2 at the stage II, 17 at the stage III, and 6 at the stage IV received the FOLFOX regimen after surgery: intravenous infusion of oxaliplatin 85 mg/m2 for 2 h on day 1, intravenous infusion of leucovorin 200 mg/m2 for 2 h on days 1-2, and intravenous bolus injection of 5-fluorouracil (5-FU) 400 mg/m2 on days 1-2, and continuous infusion of 5-FU 600 mg/m2 for 22 h on days 1-2; and this regimen was repeated every 2 weeks. The effect and adverse reactions were recorded.
Results: The median disease free survival time and overall survival time were 26.0 months and 38.0 months respectively. The frequent grade 3/4 toxicity of the FOLFOX regimen included: neutropenia (12.4%), thrombocytopenia (8.2%), and nausea (7.5%).
Conclusion: The post-operative adjuvant chemotherapy of FOLFOX regimen has expectable efficacy in treatment of gastric cancer with light and well tolerable toxicity.